Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia

Navneet S. Majhail, Ruta Brazauskas, Anna Hassebroek, Christopher N. Bredeson, Theresa Hahn, Gregory A. Hale, Mary M. Horowitz, Hillard M. Lazarus, Richard Maziarz, William A. Wood, Susan K. Parsons, Steven Joffe, J. Douglas Rizzo, Stephanie J. Lee, Brandon Hayes-Lattin

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Adolescents and young adults (AYAs) with cancer have not experienced improvements in survival to the same extent as children and older adults. We compared outcomes among children (40 years) receiving allogeneic hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML). Our cohort consisted of 900 children, 2,708 AYA, and 2,728 older adult recipients of HLA-identical sibling or unrelated donor (URD) transplantation using myeloablative or reduced-intensity/nonmyeloablative conditioning. Outcomes were assessed over three time periods (1980-1988, 1989-1997, 1998-2005) for siblings and two time periods (1989-1997, 1998-2005) for URD HCT. Analyses were stratified by donor type. Results showed overall survival for AYAs using either siblings or URD improved over time. Although children had better and older adults had worse survival compared with AYAs, improvements in survival for AYAs did not lag behind those for children and older adults. After sibling donor HCT, 5-year adjusted survival for the three time periods was 40%, 48%, and 53% for children, 35%, 41%, and 42% for AYAs, and 22%, 30%, and 34% for older adults. Among URD HCT recipients, 5-year adjusted survival for the two time periods was 38% and 37% for children, 24% and 28% for AYAs, and 19% and 23% for older adults. Improvements in survival occurred because of a reduction in risk of treatment-related mortality. The risk of relapse did not change over time. Improvements in survival among AYAs undergoing allogeneic HCT for AML have paralleled those among children and older adults.

Original languageEnglish (US)
Pages (from-to)861-873
Number of pages13
JournalBiology of Blood and Marrow Transplantation
Volume18
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Cell Transplantation
Acute Myeloid Leukemia
Young Adult
Unrelated Donors
Survival
Siblings
Transplants
Tissue Donors
Risk Reduction Behavior
Transplantation
Recurrence
Mortality

Keywords

  • Acute myeloid leukemia
  • Adolescent and young adults
  • Allogeneic
  • Hematopoietic cell transplantation
  • Survival

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia. / Majhail, Navneet S.; Brazauskas, Ruta; Hassebroek, Anna; Bredeson, Christopher N.; Hahn, Theresa; Hale, Gregory A.; Horowitz, Mary M.; Lazarus, Hillard M.; Maziarz, Richard; Wood, William A.; Parsons, Susan K.; Joffe, Steven; Rizzo, J. Douglas; Lee, Stephanie J.; Hayes-Lattin, Brandon.

In: Biology of Blood and Marrow Transplantation, Vol. 18, No. 6, 06.2012, p. 861-873.

Research output: Contribution to journalArticle

Majhail, NS, Brazauskas, R, Hassebroek, A, Bredeson, CN, Hahn, T, Hale, GA, Horowitz, MM, Lazarus, HM, Maziarz, R, Wood, WA, Parsons, SK, Joffe, S, Rizzo, JD, Lee, SJ & Hayes-Lattin, B 2012, 'Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia', Biology of Blood and Marrow Transplantation, vol. 18, no. 6, pp. 861-873. https://doi.org/10.1016/j.bbmt.2011.10.031
Majhail, Navneet S. ; Brazauskas, Ruta ; Hassebroek, Anna ; Bredeson, Christopher N. ; Hahn, Theresa ; Hale, Gregory A. ; Horowitz, Mary M. ; Lazarus, Hillard M. ; Maziarz, Richard ; Wood, William A. ; Parsons, Susan K. ; Joffe, Steven ; Rizzo, J. Douglas ; Lee, Stephanie J. ; Hayes-Lattin, Brandon. / Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia. In: Biology of Blood and Marrow Transplantation. 2012 ; Vol. 18, No. 6. pp. 861-873.
@article{f7a3aeb1533247a6b53cf1502a3023f2,
title = "Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia",
abstract = "Adolescents and young adults (AYAs) with cancer have not experienced improvements in survival to the same extent as children and older adults. We compared outcomes among children (40 years) receiving allogeneic hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML). Our cohort consisted of 900 children, 2,708 AYA, and 2,728 older adult recipients of HLA-identical sibling or unrelated donor (URD) transplantation using myeloablative or reduced-intensity/nonmyeloablative conditioning. Outcomes were assessed over three time periods (1980-1988, 1989-1997, 1998-2005) for siblings and two time periods (1989-1997, 1998-2005) for URD HCT. Analyses were stratified by donor type. Results showed overall survival for AYAs using either siblings or URD improved over time. Although children had better and older adults had worse survival compared with AYAs, improvements in survival for AYAs did not lag behind those for children and older adults. After sibling donor HCT, 5-year adjusted survival for the three time periods was 40{\%}, 48{\%}, and 53{\%} for children, 35{\%}, 41{\%}, and 42{\%} for AYAs, and 22{\%}, 30{\%}, and 34{\%} for older adults. Among URD HCT recipients, 5-year adjusted survival for the two time periods was 38{\%} and 37{\%} for children, 24{\%} and 28{\%} for AYAs, and 19{\%} and 23{\%} for older adults. Improvements in survival occurred because of a reduction in risk of treatment-related mortality. The risk of relapse did not change over time. Improvements in survival among AYAs undergoing allogeneic HCT for AML have paralleled those among children and older adults.",
keywords = "Acute myeloid leukemia, Adolescent and young adults, Allogeneic, Hematopoietic cell transplantation, Survival",
author = "Majhail, {Navneet S.} and Ruta Brazauskas and Anna Hassebroek and Bredeson, {Christopher N.} and Theresa Hahn and Hale, {Gregory A.} and Horowitz, {Mary M.} and Lazarus, {Hillard M.} and Richard Maziarz and Wood, {William A.} and Parsons, {Susan K.} and Steven Joffe and Rizzo, {J. Douglas} and Lee, {Stephanie J.} and Brandon Hayes-Lattin",
year = "2012",
month = "6",
doi = "10.1016/j.bbmt.2011.10.031",
language = "English (US)",
volume = "18",
pages = "861--873",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia

AU - Majhail, Navneet S.

AU - Brazauskas, Ruta

AU - Hassebroek, Anna

AU - Bredeson, Christopher N.

AU - Hahn, Theresa

AU - Hale, Gregory A.

AU - Horowitz, Mary M.

AU - Lazarus, Hillard M.

AU - Maziarz, Richard

AU - Wood, William A.

AU - Parsons, Susan K.

AU - Joffe, Steven

AU - Rizzo, J. Douglas

AU - Lee, Stephanie J.

AU - Hayes-Lattin, Brandon

PY - 2012/6

Y1 - 2012/6

N2 - Adolescents and young adults (AYAs) with cancer have not experienced improvements in survival to the same extent as children and older adults. We compared outcomes among children (40 years) receiving allogeneic hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML). Our cohort consisted of 900 children, 2,708 AYA, and 2,728 older adult recipients of HLA-identical sibling or unrelated donor (URD) transplantation using myeloablative or reduced-intensity/nonmyeloablative conditioning. Outcomes were assessed over three time periods (1980-1988, 1989-1997, 1998-2005) for siblings and two time periods (1989-1997, 1998-2005) for URD HCT. Analyses were stratified by donor type. Results showed overall survival for AYAs using either siblings or URD improved over time. Although children had better and older adults had worse survival compared with AYAs, improvements in survival for AYAs did not lag behind those for children and older adults. After sibling donor HCT, 5-year adjusted survival for the three time periods was 40%, 48%, and 53% for children, 35%, 41%, and 42% for AYAs, and 22%, 30%, and 34% for older adults. Among URD HCT recipients, 5-year adjusted survival for the two time periods was 38% and 37% for children, 24% and 28% for AYAs, and 19% and 23% for older adults. Improvements in survival occurred because of a reduction in risk of treatment-related mortality. The risk of relapse did not change over time. Improvements in survival among AYAs undergoing allogeneic HCT for AML have paralleled those among children and older adults.

AB - Adolescents and young adults (AYAs) with cancer have not experienced improvements in survival to the same extent as children and older adults. We compared outcomes among children (40 years) receiving allogeneic hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML). Our cohort consisted of 900 children, 2,708 AYA, and 2,728 older adult recipients of HLA-identical sibling or unrelated donor (URD) transplantation using myeloablative or reduced-intensity/nonmyeloablative conditioning. Outcomes were assessed over three time periods (1980-1988, 1989-1997, 1998-2005) for siblings and two time periods (1989-1997, 1998-2005) for URD HCT. Analyses were stratified by donor type. Results showed overall survival for AYAs using either siblings or URD improved over time. Although children had better and older adults had worse survival compared with AYAs, improvements in survival for AYAs did not lag behind those for children and older adults. After sibling donor HCT, 5-year adjusted survival for the three time periods was 40%, 48%, and 53% for children, 35%, 41%, and 42% for AYAs, and 22%, 30%, and 34% for older adults. Among URD HCT recipients, 5-year adjusted survival for the two time periods was 38% and 37% for children, 24% and 28% for AYAs, and 19% and 23% for older adults. Improvements in survival occurred because of a reduction in risk of treatment-related mortality. The risk of relapse did not change over time. Improvements in survival among AYAs undergoing allogeneic HCT for AML have paralleled those among children and older adults.

KW - Acute myeloid leukemia

KW - Adolescent and young adults

KW - Allogeneic

KW - Hematopoietic cell transplantation

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84860840686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860840686&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2011.10.031

DO - 10.1016/j.bbmt.2011.10.031

M3 - Article

C2 - 22040843

AN - SCOPUS:84860840686

VL - 18

SP - 861

EP - 873

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 6

ER -